-transparent.png){kind=logo}
Some types of intention myoclonus respond to serotonin precursor therapy (e.g., L-5-hydroxytryptophan, L-5HTP). Fluoxetine, a specific serotonin (5HT) uptake blocker, was found to have no antimyoclonic effect when administered by itself to four patients with intention myoclonus. However, in two patients with intention myoclonus responsive to L-5HTP and carbidopa, fluoxetine reduced the required dose of L-5HTP to approximately one-third, with greater antimyoclonic activity, decreased side effects, and reduction in platelet 5HT and plasma 5-hydroxyindoleacetic acid and L-5HTP concentrations. These findings further support the hypothesis that some forms of intention myoclonus are caused by a deficiency of brain 5HT, and suggest that the addition of fluoxetine to L-5HTP and carbidopa may improve antimyoclonic therapy.
M H Van Woert, and
I Magnussen, and
D Rosenbaum, and
E Chung
January 1976,
Neurology,
M H Van Woert, and
I Magnussen, and
D Rosenbaum, and
E Chung
August 1969,
JAMA,
M H Van Woert, and
I Magnussen, and
D Rosenbaum, and
E Chung
June 1974,
Lancet (London, England),
M H Van Woert, and
I Magnussen, and
D Rosenbaum, and
E Chung
August 1983,
Surgical neurology,
M H Van Woert, and
I Magnussen, and
D Rosenbaum, and
E Chung
February 1979,
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques,
M H Van Woert, and
I Magnussen, and
D Rosenbaum, and
E Chung
July 2004,
Archives of physical medicine and rehabilitation,
M H Van Woert, and
I Magnussen, and
D Rosenbaum, and
E Chung
April 1976,
Bulletin of the Los Angeles neurological societies,
M H Van Woert, and
I Magnussen, and
D Rosenbaum, and
E Chung
June 1973,
Brain : a journal of neurology,
M H Van Woert, and
I Magnussen, and
D Rosenbaum, and
E Chung
November 1995,
The American journal of psychiatry,
M H Van Woert, and
I Magnussen, and
D Rosenbaum, and
E Chung
January 1983,
Lancet (London, England),
